A phase I–II trial evaluated the efficacy of larotrectinib, a tropomyosin receptor kinase inhibitor, in TRK fusion-positive patients affected by different solid tumours (only one patient had breast cancer), showing a 1-year ORR of 71%, durable anti-tumour activity and a manageable safety profile [75]. This evidence concerns the gene NTRK1 and neoplasm.